{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:30:04Z","timestamp":1764873004413,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1053\/j.seminhematol.2008.02.003","type":"journal-article","created":{"date-parts":[[2008,3,29]],"date-time":"2008-03-29T11:11:02Z","timestamp":1206789062000},"page":"90-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1053","volume":"45","author":[{"given":"Brad","family":"Kahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2008.02.003_bib1","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin\u2019s lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib2","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2013associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/10428190701344881","article-title":"CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma","volume":"48","author":"Wilson","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib5","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib6","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib8","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib9","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib10","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib11","doi-asserted-by":"crossref","first-page":"424s","DOI":"10.1200\/jco.2006.24.18_suppl.7508","article-title":"Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma patients","volume":"24","author":"Foussard","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib12","first-page":"146a","article-title":"Mabthera (rituximab) plus cyclophosphamide, vincristine, and prednisone (CVP)","volume":"108","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib13","doi-asserted-by":"crossref","first-page":"147a","DOI":"10.1182\/blood.V108.11.484.484","article-title":"Addition of rituximab to first line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma\u20144 year follow up of a phase III trial of the East German Study Group Hematology and Oncology","volume":"108","author":"Herold","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib14","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib16","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib17","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: Phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib18","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","article-title":"Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib19","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib20","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/cncr.22342","article-title":"A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma","volume":"107","author":"Micallef","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib21","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/019262339902700115","article-title":"Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody","volume":"27","author":"Ryan","year":"1999","journal-title":"Toxicologic pathology"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib23","first-page":"647","article-title":"Serum vascular endothelial growth factor is often elevated in disseminated cancer","volume":"3","author":"Salven","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib24","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1073\/pnas.180316097","article-title":"Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas","volume":"97","author":"Lossos","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib25","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1080\/1042819031000123519","article-title":"Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin\u2019s lymphoma","volume":"44","author":"Hazar","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1080\/10428190600563821","article-title":"Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis","volume":"47","author":"Ganjoo","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib27","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.02.003_bib28","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:18:55Z","timestamp":1758521935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196308000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0037196308000048"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.02.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin\u2019s Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}